These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36384890)

  • 1. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
    Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
    BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
    Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
    Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.
    Zheng B; Campbell J; Carr EJ; Tazare J; Nab L; Mahalingasivam V; Mehrkar A; Santhakumaran S; Steenkamp R; Loud F; Lyon S; Scanlon M; Hulme WJ; Green ACA; Curtis HJ; Fisher L; Parker E; Goldacre B; Douglas I; Evans S; MacKenna B; Bell S; Tomlinson LA; Nitsch D;
    Clin Kidney J; 2023 Nov; 16(11):2048-2058. PubMed ID: 37915915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY.
    Green ACA; Curtis HJ; Higgins R; Nab L; Mahalingasivam V; Smith RM; Mehrkar A; Inglesby P; Drysdale H; DeVito NJ; Croker R; Rentsch CT; Bhaskaran K; Tazare J; Zheng B; Andrews CD; Bacon SCJ; Davy S; Dillingham I; Evans D; Fisher L; Hickman G; Hopcroft LEM; Hulme WJ; Massey J; MacDonald O; Morley J; Morton CE; Park RY; Walker AJ; Ward T; Wiedemann M; Bates C; Cockburn J; Parry J; Hester F; Harper S; Douglas IJ; Evans SJW; Goldacre B; Tomlinson LA; MacKenna B
    BMJ Med; 2023; 2(1):e000276. PubMed ID: 36936265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
    Patel V; Yarwood MJ; Levick B; Gibbons DC; Drysdale M; Kerr W; Watkins JD; Young S; Pierce BF; Lloyd EJ; Birch HJ; Kamalati T; Brett SJ
    Curr Med Res Opin; 2024 Aug; 40(8):1323-1334. PubMed ID: 38975862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
    Xie Y; Bowe B; Al-Aly Z
    BMJ; 2023 Mar; 380():e072705. PubMed ID: 36882199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland.
    Tibble H; Mueller T; Proud E; Hall E; Kurdi A; Robertson C; Bennie M; Woolford L; Laidlaw L; Sterniczuk K; Sheikh A
    NPJ Prim Care Respir Med; 2024 Jun; 34(1):17. PubMed ID: 38942748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19.
    Bechman K; Green AC; Russell MD; Yang Z; Zheng B; Norton S; Smith RM; Mehrkar A; Bacon SCJ; Goldacre B; MacKenna B; Galloway JB;
    J Infect; 2024 Sep; 89(3):106227. PubMed ID: 39019401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
    Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
    JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
    Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.